101. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of amino acids 56-62 and 64-70 of SEQ ID NO: 39 and amino acid 63 of SEQ ID NO: 39 is substituted with a valine. SQ 4

102. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of amino acids 56-64 and 66-70 of SEQ ID NO: 39 and amino acid 65 of SEQ ID NO: 39 is substituted with a valine. SQ 3

103. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of amino acids 448-450 and 452-462 of SEQ ID NO: 39 and amino acid 451 of SEQ ID NO: 39 is substituted with a phenylalanine. SQ 10

104. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of amino acids 448-455 and 457-462 of SEQ ID NO: 39 and amino acid 456 of SEQ ID NO: 39 is substituted with a valine. SQ 11

105. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of 450-455 and 457-462 of SEQ ID NO: 39 and amino acid 456 is substituted with a valine. SQ 12 =SQ 12

106. (New) The immunogenic peptide of claim 100, wherein the peptide is a peptide selected from the group consisting of:

(A) a peptide consisting essentially of amino acids 56, 57, and 59-70 of SEQ ID NO: 39 and amino acid 58 of SEQ ID NO: 39 is substituted with a phenylalanine (SQ 18) or a valine (SQ 19); and

(B) a peptide consisting essentially of amino acids 448 and 450-462 of SEQ ID NO: 39 and amino acid 449 of SEQ ID NO: 39 is substituted with a phenylalanine or a glutamine; SQ 8 SQ 9

107. (New) The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 56-70 of SEQ ID NO: 39. SQ 1

108. (New) The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 448-462 of SEQ ID NO: 39. SQ 6

109. (New) The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 57-70 of SEQ ID NO: 39.

110. The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 449-462 of SEQ ID NO: 39.

111. (New) The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 450-462 of SEQ ID NO: 39.

112. (New) The immunogenic peptide of claim 100, wherein the MHC Class II molecule is Human Leukocyte Antigen (HLA)-DR.

113. (New) The immunogenic peptide of claim 112, wherein the HLA-DR is HLA-DRB1*0401.

114. (New) The immunogenic peptide of claim 100 linked to an MHC Class II molecule, or a portion thereof.

115. (New) The immunogenic peptide of claim 114, wherein the portion of the MHC Class II molecule is the β chain of the MHC Class II molecule.

116. (New) A composition comprising an immunogenic peptide of claim 100.

117. (New) A composition comprising an immunogenic peptide of claim 114.

118. (New) A method of inducing $CD4^+$ T lymphocytes to respond to melanoma, which method comprises:

(i) contacting antigen presenting cells with a composition of claim 116 *in vitro*, and

(ii) simultaneously or subsequently exposing $CD4^+$ T lymphocytes to the antigen presenting cells *in vitro*,

whereupon the $CD4^+$ T lymphocytes are induced to respond to melanoma.

119. (New) The method of claim 118, wherein the $CD4^+$ T lymphocytes are obtained from a host and the method further comprises:

(iii) administering the $CD4^+$ T lymphocytes to the host.

120. (New) The method of claim 119, wherein the host is a mammal.

121. (New) The method of claim 120, wherein the mammal is a human.

122. (New) The method of claim 119, wherein the antigen presenting cells are obtained from the host.

123. (New) A method of inducing $CD4^+$ T lymphocytes in a host to respond to melanoma, which method comprises:

(i) contacting antigen presenting cells with a composition of claim ~~116~~ *in vitro*, and

(ii) subsequently exposing $CD4^+$ T lymphocytes in the host to the antigen presenting cells by administering the antigen presenting cells to the host,

whereupon the $CD4^+$ T lymphocytes in the host are induced to respond to melanoma.

124. (New) The method of claim 123, wherein the host is a mammal.

125. (New) The method of claim 124, wherein the mammal is a human.

126. (New) The method of claim 123, wherein the antigen presenting cells are obtained from the host.

127. (New) A method of inducing $CD4^+$ T lymphocytes in a host to respond to melanoma, which method comprises administering the composition of claim 116 to the host, whereupon the $CD4^+$ T lymphocytes in the host are induced to respond to melanoma.

128. (New) A method of inducing $CD4^+$ T lymphocytes to respond to melanoma, which method comprises:

(i) contacting antigen presenting cells with a composition of claim 117 *in vitro*, and

(ii) simultaneously or subsequently exposing $CD4^+$ T lymphocytes to the antigen presenting cells *in vitro*,

whereupon the $CD4^+$ T lymphocytes are induced to respond to melanoma.

129. (New) The method of claim 128, wherein the $CD4^+$ T lymphocytes are obtained from a host and the method further comprises:

(iii) administering the $CD4^+$ T lymphocytes to the host.

130. (New) The method of claim 129, wherein the host is a mammal.

131. (New) The method of claim 130, wherein the mammal is a human.

132. (New) The method of claim 128, wherein the antigen presenting cells are obtained from the host.

133. (New) A method of inducing $CD4^+$ T lymphocytes in a host to respond to melanoma, which method comprises:

(i) contacting antigen presenting cells with a composition of claim 117 *in vitro*, and

(ii) subsequently exposing $CD4^+$ T lymphocytes in the host to the antigen presenting cells by administering the antigen presenting cells to the host,

whereupon the $CD4^+$ T lymphocytes in the host are induced to respond to melanoma.

134. (New) The method of claim 133, wherein the host is a mammal.

135. (New) The method of claim 134, wherein the mammal is a human.

136. (New) The method of claim 133, wherein the antigen presenting cells are obtained from the host.

137. (New) A method of inducing $CD4^+$ T lymphocytes in a host to respond to melanoma, which method comprises administering the composition of claim 117 to the host, whereupon the $CD4^+$ T lymphocytes in the host are induced to respond to melanoma.